ES2863274T3 - Biomarcador de muerte celular - Google Patents

Biomarcador de muerte celular Download PDF

Info

Publication number
ES2863274T3
ES2863274T3 ES17771553T ES17771553T ES2863274T3 ES 2863274 T3 ES2863274 T3 ES 2863274T3 ES 17771553 T ES17771553 T ES 17771553T ES 17771553 T ES17771553 T ES 17771553T ES 2863274 T3 ES2863274 T3 ES 2863274T3
Authority
ES
Spain
Prior art keywords
bap1
protein
wild
type
cell death
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17771553T
Other languages
English (en)
Inventor
Samuel Janes
Krishna Kolluri
Ultan Mcdermott
Neelam Kumar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Application granted granted Critical
Publication of ES2863274T3 publication Critical patent/ES2863274T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • G01N2496/05—Reference solutions for assays of biological material containing blood cells or plasma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un método para determinar si la célula cancerosa de un individuo es sensible a la muerte celular inducida por ligando del receptor de muerte (DRL), el método comprende detectar, en una muestra biológica tomada del individuo, para: (i) la presencia de un gen BAP1 mutante o proteína BAP1 mutante; (ii) un nivel reducido de expresión de un gen BAP1 de tipo salvaje o una concentración de proteína BAP1 de tipo salvaje más baja en comparación con el nivel de expresión o la concentración de proteína en una célula de referencia que es una célula con BAP1 de tipo salvaje, que es resistente a la muerte celular inducida por DRL; o (iii) la reducción o no unión de una proteína ASXL a una proteína BAP1 de tipo salvaje en comparación con el nivel de unión en una célula de referencia que es una célula con BAP1 de tipo salvaje, que es resistente a la muerte celular inducida por DRL; en donde la presencia, en la muestra, del mutante del gen BAP1 o la proteína BAP1 mutante, o de un nivel reducido de expresión del gen BAP1 de tipo salvaje o una concentración de proteína más baja, o la reducción o no unión de una proteína ASXL a una proteína BAP1 de tipo salvaje, es indicativo de que la célula cancerosa del individuo es sensible a la muerte celular inducida por DRL.
ES17771553T 2016-09-16 2017-09-15 Biomarcador de muerte celular Active ES2863274T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1615842.0A GB201615842D0 (en) 2016-09-16 2016-09-16 Cell death biomarker
PCT/GB2017/052733 WO2018051110A1 (en) 2016-09-16 2017-09-15 Cell death biomarker

Publications (1)

Publication Number Publication Date
ES2863274T3 true ES2863274T3 (es) 2021-10-11

Family

ID=57288813

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17771553T Active ES2863274T3 (es) 2016-09-16 2017-09-15 Biomarcador de muerte celular

Country Status (8)

Country Link
US (2) US11789012B2 (es)
EP (1) EP3513192B1 (es)
JP (1) JP7211936B2 (es)
AU (1) AU2017327994B2 (es)
DK (1) DK3513192T3 (es)
ES (1) ES2863274T3 (es)
GB (1) GB201615842D0 (es)
WO (1) WO2018051110A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
CN112961864A (zh) * 2021-02-26 2021-06-15 广州市妇女儿童医疗中心 突变的asxl3基因及应用
CN114478797B (zh) * 2021-11-24 2023-10-27 中山大学附属第五医院 一种靶向ddx24蛋白的水解靶向嵌合体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070037165A1 (en) * 2000-09-08 2007-02-15 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20020169123A1 (en) * 2001-02-27 2002-11-14 The Trustees Of The University Of Pennsylvania Regulating apoptosis in TRAIL-resistant cancer cells, while protecting normal, non-cancerous cells
ZA200900043B (en) * 2006-06-20 2010-03-31 Genentech Inc Methods and materials for observing apoptosis by detecting fragments of clathrin-pathway components
GB2484003B (en) * 2010-09-23 2013-04-24 Univ Washington Compositions and methods for detecting uveal melanoma cancer metastasis risk
US20140011696A1 (en) * 2011-02-16 2014-01-09 Thomas Wiesner Bap1 mutational analysis in determining susceptibility to, prognosis of, and treatment of melanocytic neoplasia
WO2014156527A1 (ja) * 2013-03-28 2014-10-02 国立大学法人東北大学 食道癌の発症リスクを判定する方法及びキット
CN105705504A (zh) * 2013-10-10 2016-06-22 密歇根大学董事会 去泛素化酶抑制剂及其使用方法
US20160101071A1 (en) * 2014-04-28 2016-04-14 Wisconsin Alumni Research Foundation Combination cancer treatment
CA2948883A1 (en) * 2014-06-02 2015-12-10 Pharmakea, Inc. Deubiquitinase inhibitors
CA2952285A1 (en) * 2014-06-19 2015-12-23 Memorial Sloan-Kettering Cancer Center Biomarkers for response to ezh2 inhibitors

Also Published As

Publication number Publication date
US20190257818A1 (en) 2019-08-22
DK3513192T3 (da) 2021-03-29
EP3513192A1 (en) 2019-07-24
JP2020500502A (ja) 2020-01-16
AU2017327994A1 (en) 2019-04-04
WO2018051110A1 (en) 2018-03-22
US20240118266A1 (en) 2024-04-11
EP3513192B1 (en) 2020-12-23
GB201615842D0 (en) 2016-11-02
AU2017327994B2 (en) 2023-09-14
US11789012B2 (en) 2023-10-17
JP7211936B2 (ja) 2023-01-24

Similar Documents

Publication Publication Date Title
MX2022001463A (es) Metodo y sistema para la determinacion no destructiva in ovo del genero aviar.
MX2008009592A (es) Metodos y composiciones para identificar pacientes con una probabilidad incrementada de tener cancer de ovario.
TR201907389T4 (tr) Meme kanserinden kaynaklanan metastazlı kemik kanserinin prognozu ve tedavisine yönelik yöntem.
EP3839510A3 (en) Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
EP4180531A3 (en) Nasal epithelium gene expression signature and classifier for the prediction of lung cancer
AR095363A1 (es) Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1
EA201070349A1 (ru) Определение вариаций количества копий, способы и системы
MX2015011362A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
ES2863274T3 (es) Biomarcador de muerte celular
MX368394B (es) Receptor alfa de folato como marcador de diagnostico y pronostico para canceres que expresan receptor alfa de folato.
TR201904386T4 (tr) Nükleotidleri içeren nükleozomların saptanmasına yönelik yöntem.
NZ629074A (en) Biomarkers for gastric cancer and uses thereof
AR105618A1 (es) Metilación del promotor del ligando al receptor de muerte programada (pd-l1) en cáncer
WO2006055880A3 (en) Diagnostic pkm2 methods and compositions
HK1149956A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
HK1115636A1 (en) Use of cyfra 21-1 as a marker for colorectal cancer cyfra 21-1
AR099856A1 (es) Métodos para diagnosticar y tratar la enfermedad de intestino inflamado
EA201691505A1 (ru) Детектирование экспрессии простатического специфического мембранного антигена (psma) на циркулирующих опухолевых клетках (ctc)
EA201790549A1 (ru) Предиктивные и прогностические биомаркеры, связанные с антиангиогенной терапией злокачественной опухоли
ATE471512T1 (de) Verwendung des proteins s100a 12 als marker für kolorektalkarzinom
Buser et al. Quantitative proteomics reveals reduction of endocytic machinery components in gliomas
BR112017011545A2 (pt) ensaio de desvio de mobilidade homogênea indireto para a detecção de produtos biológicos nas amostras do paciente
BR112013014195A2 (pt) Método para a identificação de um paciente, composição, uso de bevacizumabe para a preparação de uma composição farmacêutica, método para o tratamento de um distúrbio proliferativo e composição, uso ou método
MX2016009490A (es) Ensayo novedoso para detectar periostina humana.
ATE468535T1 (de) Verwendung von nnmt als marker für lungenkrebs